PSMA
1 EU-approved indication of 1 drug needs a PSMA result, in 1 tumour type, most of them in prostate cancer.
Approved indications1
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| Prostate cancer1 | ||||
| + androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition | 3L+ metastatic | Castration-resistant only; After AR pathway inhibition and taxane-based chemotherapy; Progressive disease | ||
PSMA by tumour
Label wording1
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Lutetium (177Lu) vipivotide tetraxetan (Pluvicto)
Pluvicto in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane-based chemotherapy (see section 5.1).